Jon Congleton; Chief Executive Officer, Director; Mineralys Therapeutics Inc. David Rodman; Chief Medical Officer ...

Reduced baroreflex sensitivity is tied to an increased risk for dementia in older adults who do not take antihypertensive medications.

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 – – Completed enrollment in Explore-CKD Phase 2 trial and anticipate ...

Vitamin D3 supplementation was associated with antihypertensive effects without significant between-dose differences among overweight older adults.

CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and resistant hypertension. He ...

Q4 2024 Earnings Call Transcript February 12, 2025 Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

although its use has been tainted by recent findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT was a large, simple trial, designed in a ...

Background Left ventricular (LV) mass is closely associated with atherosclerotic heart disease, but the mechanisms are not well defined. This study aimed to evaluate the risk factors associated with ...

AVEO Oncology, an LG Chem company ("AVEO"), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives, announced today two poster presentations ...

Frailty nurse specialist Linda Nazarko advises on what nurses in general practice need to be aware of when reviewing and ...

Consultant Geriatrician at Sunway Medical Centre, Sunway City (SMC), Dr Edward Chong Kah Chun, said physical decline is a ...